Trials / Completed
CompletedNCT00567619
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 900 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency \& severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists \- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca
Conditions
Timeline
- Start date
- 2007-07-01
- First posted
- 2007-12-05
- Last updated
- 2008-02-18
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00567619. Inclusion in this directory is not an endorsement.